Aguero Cinthya, Dhaynaut Maeva, Amaral Ana C, Moon S-H, Neelamegam Ramesh, Scapellato Margaret, Carazo-Casas Carlos, Kumar Sunny, El Fakhri Georges, Johnson Keith, Frosch Matthew P, Normandin Marc D, Gómez-Isla Teresa
MassGeneral Institute for NeuroDegenerative Disease, Charlestown, MA, USA.
Department of Neurology, Massachusetts General Hospital, WACC Suite 715, 15th Parkman St., Boston, MA, 02114, USA.
Acta Neuropathol. 2024 Jan 27;147(1):25. doi: 10.1007/s00401-023-02672-z.
We and others have shown that [F]-Flortaucipir, the most validated tau PET tracer thus far, binds with strong affinity to tau aggregates in Alzheimer's (AD) but has relatively low affinity for tau aggregates in non-AD tauopathies and exhibits off-target binding to neuromelanin- and melanin-containing cells, and to hemorrhages. Several second-generation tau tracers have been subsequently developed. [F]-MK-6240 and [F]-PI-2620 are the two that have garnered most attention. Our recent data indicated that the binding pattern of [F]-MK-6240 closely parallels that of [F]-Flortaucipir. The present study aimed at the direct comparison of the autoradiographic binding properties and off-target profile of [F]-Flortaucipir, [F]-MK-6240 and [F]-PI-2620 in human tissue specimens, and their potential binding to monoamine oxidases (MAO). Phosphor-screen and high resolution autoradiographic patterns of the three tracers were studied in the same postmortem tissue material from AD and non-AD tauopathies, cerebral amyloid angiopathy, synucleopathies, transactive response DNA-binding protein 43 (TDP-43)-frontotemporal lobe degeneration and controls. Our results show that the three tracers show nearly identical autoradiographic binding profiles. They all strongly bind to neurofibrillary tangles in AD but do not seem to bind to a significant extent to tau aggregates in non-AD tauopathies pointing to their limited utility for the in vivo detection of non-AD tau lesions. None of them binds to lesions containing β-amyloid, α-synuclein or TDP-43 but they all show strong off-target binding to neuromelanin and melanin-containing cells, as well as weaker binding to areas of hemorrhage. The autoradiographic binding signals of the three tracers are only weakly displaced by competing concentrations of selective MAO-B inhibitor deprenyl but not by MAO-A inhibitor clorgyline suggesting that MAO enzymes do not appear to be a significant binding target of any of them. These findings provide relevant insights for the correct interpretation of the in vivo behavior of these three tau PET tracers.
我们及其他研究人员已表明,[F]-氟替卡匹尔是目前验证程度最高的tau蛋白正电子发射断层显像(PET)示踪剂,它与阿尔茨海默病(AD)中的tau蛋白聚集体具有很强的亲和力,但对非AD tau蛋白病中的tau蛋白聚集体亲和力相对较低,并且会与含神经黑色素和黑色素的细胞以及出血部位发生非靶向结合。随后开发了几种第二代tau蛋白示踪剂。[F]-MK-6240和[F]-PI-2620是最受关注的两种。我们最近的数据表明,[F]-MK-6240的结合模式与[F]-氟替卡匹尔非常相似。本研究旨在直接比较[F]-氟替卡匹尔、[F]-MK-6240和[F]-PI-2620在人体组织标本中的放射自显影结合特性和非靶向分布情况,以及它们与单胺氧化酶(MAO)的潜在结合。在来自AD和非AD tau蛋白病、脑淀粉样血管病、突触核蛋白病、反应性DNA结合蛋白43(TDP-43)-额颞叶变性的相同尸检组织材料以及对照中,研究了这三种示踪剂的磷屏和高分辨率放射自显影模式。我们的结果表明,这三种示踪剂显示出几乎相同的放射自显影结合图谱。它们都与AD中的神经原纤维缠结强烈结合,但似乎在很大程度上不与非AD tau蛋白病中的tau蛋白聚集体结合,这表明它们在体内检测非AD tau病变方面的效用有限。它们都不与含有β淀粉样蛋白、α突触核蛋白或TDP-43的病变结合,但它们都显示出与神经黑色素和含黑色素的细胞有很强的非靶向结合,以及与出血部位有较弱的结合。三种示踪剂的放射自显影结合信号仅被选择性MAO-B抑制剂司来吉兰的竞争浓度微弱取代,而未被MAO-A抑制剂氯吉兰取代,这表明MAO酶似乎不是它们任何一种的重要结合靶点。这些发现为正确解释这三种tau蛋白PET示踪剂的体内行为提供了相关见解。